Abstract | PURPOSE: METHODS AND MATERIALS: In 23 adult patients, surgery, postoperative radiotherapy (60 Gy in 30 daily fractions within 6 weeks), and adjuvant modified chemotherapy ( procarbazine 60 mg/m(2) on Days 1-14, lomustine 100 mg/m(2) on Day 1, and vincristine 1.4 mg/m(2) [maximum 2 mg] on Days 1 and 8) were administered every 6 weeks for up to six cycles or until progression occurred. RESULTS: The median follow-up was 116 months for all patients. The median survival time was 118 months, and the 5-year and 10-year survival rate was 57% and 47%, respectively. The median time to tumor progression was 78 months, with a 5-year and 10-year progression-free survival rate of 52% and 39%, respectively. Gender, age, Karnofsky performance status, location, and histologic type did not influence survival. Patients with tumors <or=4 cm did better than those with tumors >4 cm (p = 0.0470), as did those with total tumor resection compared with those with subtotal tumor resection or biopsy only (p = 0.0024). Gender, Karnofsky performance status, location, and histologic type did not influence progression-free survival, but younger age (p = 0.0389), smaller tumor size (p = 0.0357), and more radical surgery (p = 0.0033) correlated positively with it. Acute high-grade (Grade 3 or worse) chemotherapy-related toxicity was mainly hematologic, with 3 patients (13%) experiencing acute Grade 4 toxicity. CONCLUSION: The results of this 10-year update confirmed that the trimodality approach is effective in patients with anaplastic oligodendroglioma and oligoastrocytoma.
|
Authors | Branislav Jeremic, Biljana Milicic, Danica Grujicic, Miroslav Samardzic, Vaso Antunovic, Aleksandar Dagovic, Jasna Aleksandrovic |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 59
Issue 2
Pg. 509-14
(Jun 01 2004)
ISSN: 0360-3016 [Print] United States |
PMID | 15145170
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Topics |
- Astrocytoma
(drug therapy, mortality, radiotherapy, surgery)
- Brain Neoplasms
(drug therapy, mortality, radiotherapy, surgery)
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Oligodendroglioma
(drug therapy, mortality, radiotherapy, surgery)
- Survival Rate
|